Peer-reviewed veterinary case report
Humanin blood levels predict heart valve disease in dogs compared
By Mangkhang, K et al.·Published in Polish journal of veterinary sciences·2018·Small Animal Hospital·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
- Species:
- dog
Plain-English summary
A group of older dogs with myxomatous mitral valve disease (MMVD), a common heart condition, was studied to see if a protein called humanin could help predict how severe their heart failure might become. The dogs were divided into groups based on the severity of their condition, and tests showed that dogs with more advanced heart failure had lower levels of humanin in their blood. This suggests that measuring humanin levels could be useful for detecting heart problems earlier than traditional tests. The study indicates that lower humanin levels might help veterinarians assess the progression of heart disease in dogs.
People also search for: dog heart disease symptoms · myxomatous mitral valve disease in dogs · humanin levels in dogs · heart failure treatment for dogs
Abstract
Myxomatous mitral valve disease (MMVD) is a cardiac condition commonly found in older dogs. The disease process can lead to heart failure (HF). In HF, an increase of reactive oxygen species (ROS) and abnormal mitochondrial activity, as well as apoptosis, have been reported. Humanin (HN) is a polypeptide that has a cardioprotective effect against apoptosis and oxidative stress. The purposes of this study were (1) to investigate the potential role of plasma HN as a cardiac biomarker to predict disease progression of MMVD, and (2) to compare plasma HN concentrations with plasma NT-pro BNP concentrations. Thirty-one dogs were included in the study. The dogs were separated into four groups: Group 1 was healthy dogs (n = 8), Group 2 was MMVD class B (n = 8), Group 3 was MMVD class C (n = 8), and Group 4 was MMVD class D (n = 7). All dogs were given a physical examination, thoracic radiography, echocardiography, and samples of their blood were collected for hematology and blood chemistry analysis. Levels of plasma HN and plasma NT-proBNP were also investigated. The results showed that plasma HN levels were lower in the dogs with MMVD and that lower plasma HN levels were associated with greater severity of MMVD-induced HF. It was possible to observe changes in plasma HN levels at a less severe disease stage than plasma NT-proBNP in dogs with MMVD. These findings sug- gest that a decreased plasma HN level can be used as a biomarker to identify dogs with MMVD-induced HF.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30605282/